Price T Rowe Associates Inc. MD Cuts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Price T Rowe Associates Inc. MD trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,304,832 shares of the medical research company’s stock after selling 1,611,792 shares during the period. Thermo Fisher Scientific makes up about 0.6% of Price T Rowe Associates Inc. MD’s holdings, making the stock its 25th biggest holding. Price T Rowe Associates Inc. MD’s holdings in Thermo Fisher Scientific were worth $4,630,086,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $31,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Navigoe LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.7%

NYSE:TMO opened at $494.8160 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $186.85 billion, a PE ratio of 28.62, a P/E/G ratio of 2.66 and a beta of 0.74. The business’s 50 day moving average is $439.69 and its two-hundred day moving average is $458.78.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The business’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 9.95%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMO. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Barclays boosted their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 24th. Finally, Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $593.00.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,400 shares of company stock worth $8,345,792 in the last three months. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.